ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 594,00
-0,13%
Dow Jones
42 208,22
0,00%
DAX
18 957,72
-0,16%
Brent Oil
73,435
-1,51%
Bitcoin
63 694,84
-0,89%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Hikma Pharmaceuticals Plc (HIK)

  7. Hikma Pharmaceuticals Plc (HIK) Actualités

HIK

Hikma Pharmaceuticals (HIK)

Hikma Pharmaceuticals Plc
De:
Trier par:
 Showing the most relevant articles for your search:LSE:HIK
DateHeureSourceTitreSymboleSociété
24/09/202411h09RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
10/09/202410h09Alliance NewsAlliance NewsHikma Pharmaceuticals completes acquisition of Xellia's FDF businessLSE:HIKHikma Pharmaceuticals Plc
10/09/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma completes Xellia acquisitionLSE:HIKHikma Pharmaceuticals Plc
03/09/202413h46Alliance NewsAlliance NewsIN THE KNOW: Berenberg sees "standout" year at Hikma's Injectibles armLSE:HIKHikma Pharmaceuticals Plc
20/08/202418h15PR Newswire (US)Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention DayLSE:HIKHikma Pharmaceuticals Plc
15/08/202421h18PR Newswire (US)KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 monthsLSE:HIKHikma Pharmaceuticals Plc
13/08/202411h16Alliance NewsAlliance NewsIN BRIEF: Hikma executive Bassam Kanaan sells 45,000 sharesLSE:HIKHikma Pharmaceuticals Plc
08/08/202412h33Alliance NewsAlliance NewsHikma Pharmaceuticals raises guidance as first-half profit jumps 43%LSE:HIKHikma Pharmaceuticals Plc
08/08/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Half-year ReportLSE:HIKHikma Pharmaceuticals Plc
29/07/202417h08RNS Regulatory NewsHikma Pharmaceuticals Plc Director DeclarationLSE:HIKHikma Pharmaceuticals Plc
15/07/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Notice of ResultsLSE:HIKHikma Pharmaceuticals Plc
01/07/202415h47RNS Regulatory NewsHikma Pharmaceuticals Plc Total Voting RightsLSE:HIKHikma Pharmaceuticals Plc
17/06/202410h14Alliance NewsAlliance NewsHikma adds scale to US injectables business with Xellia acquisitionLSE:HIKHikma Pharmaceuticals Plc
17/06/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma acquires Xellia’s assetsLSE:HIKHikma Pharmaceuticals Plc
11/06/202414h05Alliance NewsAlliance NewsIN THE KNOW: Citi lifts Hikma price target amid positive industry dataLSE:HIKHikma Pharmaceuticals Plc
25/04/202415h28RNS Regulatory NewsHikma Pharmaceuticals Plc Result of AGMLSE:HIKHikma Pharmaceuticals Plc
25/04/202411h15Alliance NewsAlliance NewsHikma Pharmaceuticals backs outlook after making strong start to 2024LSE:HIKHikma Pharmaceuticals Plc
25/04/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Trading StatementLSE:HIKHikma Pharmaceuticals Plc
15/04/202417h43RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma appoints new President of Generics businessLSE:HIKHikma Pharmaceuticals Plc
02/04/202410h50RNS Regulatory NewsHikma Pharmaceuticals Plc Block listing Interim ReviewLSE:HIKHikma Pharmaceuticals Plc
22/03/202410h21RNS Regulatory NewsHikma Pharmaceuticals Plc Annual Financial Report and Notice of AGMLSE:HIKHikma Pharmaceuticals Plc
22/02/202410h42Alliance NewsAlliance NewsTOP NEWS: Hikma boosts dividend after year of "significant progress"LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h09Alliance NewsAlliance News*Hikma Pharmaceuticals says core operating profit to be in range of USD660m to USD700mLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h08Alliance NewsAlliance News*Hikma Pharmaceuticals expect revenue to grow in the range of 4% to 6%LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h08Alliance NewsAlliance News*Hikma Pharmaceuticals confident that strategy will continue to deliver growth in 2024LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h07Alliance NewsAlliance News*Hikma Pharmaceuticals declares FY dividend of 73 US cents per share vs 56 cents YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h06Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 pretax profit USD520m vs USD233m YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h06Alliance NewsAlliance News*REPEAT: Hikma Pharmaceuticals 2023 revenue USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h05Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Final ResultsLSE:HIKHikma Pharmaceuticals Plc
 Showing the most relevant articles for your search:LSE:HIK

Dernières Valeurs Consultées

TSXV
BMX
Boreal Metals
TG
A28R5B
Banco Santander
LSE
BS89
Virgin Mon.perp
COIN
KODETH
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés